Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Anker
Johnny Anker, Paulowna NL
| Patent application number | Description | Published |
|---|---|---|
| 20090176983 | Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal - The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114. | 07-09-2009 |
Johnny Anker, Anna Paulowna NL
| Patent application number | Description | Published |
|---|---|---|
| 20090270352 | Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal - The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114. | 10-29-2009 |
Luis E. Anker US
| Patent application number | Description | Published |
|---|---|---|
| 20120014102 | VERSATILE LIGHTING UNITS - Systems and methods which provide a versatile lighting module which may be utilized alone or in combination with other lighting modules to provide any number of lighting unit configurations are shown. Lighting modules of embodiments herein are adapted to facilitate electrical connection, whether to one or more power supply and/or to one or more other lighting module, along any portion of the entire periphery of the lighting module. Accordingly, lighting modules may be coupled together in any orientation, geometry, and topology to cooperate as a light source having various desired characteristics according to embodiments herein. | 01-19-2012 |
Stefan Anker, Berlin DE
| Patent application number | Description | Published |
|---|---|---|
| 20080269179 | Use of Megestrol Acetate for the Treatment of Obstructive Pulmonary Diseases - The present invention relates to the treatment of patients suffering from pulmonary diseases, in particular from chronic obstructive pulmonary disease (COPD), bronchial asthma, cystic fibrosis and chronic cough in particular as caused by ACE-Inhibitors using megestrol acetate. | 10-30-2008 |
| 20090197851 | THERAPY AND USE OF COMPOUNDS IN THERAPY - A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. | 08-06-2009 |
| 20090248101 | METHOD FOR ENHANCING THE PERFORMANCE AND GENERAL CONDITION OF A SUBJECT - The invention concerns the therapy with a cardiac resynchronisation device (CRT) and/or therapy with an automated internal cardiac defibrilator (ICD) for the treatment of subjects without cardiac diseases, in particular patients with any cancer or patients with cachexia due to acute or chronic illness other than cardiac illness, including malignant tumor disease, COPD, chronic renal failure, liver cirrhosis, chronic infections, and/or AIDS. | 10-01-2009 |
| 20100143953 | DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY BY MEANS OF NATRIURETIC PEPTIDES FOR NYHA I PATIENTS - The invention relates to a method for the diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency for NYHA I patients, wherein a determination of the proANP marker, NT-proANP marker, or fragments or partial peptides thereof is carried out parallel to a determination of BNP, proBNP, and/or NT-proBNP on patients to be examined. | 06-10-2010 |
| 20100285493 | METHOD FOR DETERMINING AMINO-TERMINAL PROANP IN PATIENTS HAVING A CARDIAC DISEASE OR BEING SUSPECTED OF DEVELOPING OR HAVING A CARDIAC DISEASE - The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANP or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention. | 11-11-2010 |
Stefan Dietmar Anker, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20090023639 | Methods of Treatment - A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia. | 01-22-2009 |
Tal Anker, Elishema IL
| Patent application number | Description | Published |
|---|---|---|
| 20080282246 | COMPILER AIDED TICKET SCHEDULING OF TASKS IN A COMPUTING SYSTEM - A method of scheduling tasks for execution in a computer system includes determining a dynamic worst case execution time for a non-periodic task. The dynamic worst case execution time is based on an actual execution path of the non-periodic task. An available time period is also determined, wherein the available time period is an amount of time available for execution of the non-periodic task. The non-periodic task is scheduled for execution if the dynamic worst case execution time is less than the available time period. | 11-13-2008 |
Tal Anker, Modiin IL
| Patent application number | Description | Published |
|---|---|---|
| 20080201772 | Method and Apparatus for Deep Packet Inspection for Network Intrusion Detection - In a method of determining whether a data stream includes unauthorized data, the data stream is analyzed using a hardware filter to detect a presence of one or more of a first set of patterns in the data stream. It is determined whether a packet in the data stream belongs to one of a plurality of data flows to be further inspected based on the analysis of the data stream by the hardware filter. A set of rules is applied to the packet to produce rule match status data if it is determined that the packet belongs to one of the plurality of data flows to be further inspected. The packet is analyzed to determine if the packet includes unauthorized data using software stored on a computer-readable medium and implemented on a processor if the rule match status data indicates that the packet potentially includes unauthorized data. | 08-21-2008 |
| 20090323383 | COMPARING DATA REPRESENTATIONS TO STORED PATTERNS - A search engine includes a storage module to store a plurality of data patterns, a plurality of busses to receive a plurality of representations of a search word, a selector corresponding to at least one of the plurality of data patterns to select one of the plurality of representations of the search word for comparing to the at least one of the plurality of data patterns, and a logic circuit operatively coupled to the storage module, to the plurality of busses, and to the selector to compare the selected one of the plurality of representations of the search word to the at least one of the plurality of data patterns. | 12-31-2009 |
Willem Anker, Ellerbek DE
| Patent application number | Description | Published |
|---|---|---|
| 20090088483 | AQUEOUS SUSPENSIONS OR DISPERSIONS OF INORGANIC PIGMENTS CONTAINING A MIXTURE CONSISTING OF DIALDEHYDES AND FORMALDEHYDE CLEAVERS - The invention relates to aqueous suspensions or dispersions (slurries) of minerals and/or fillers and/or pigments containing one or more dialdehydes and one or more formaldehyde cleavers, and to the use of mixtures consisting of one or more dialdehydes and of one or more formaldehyde cleavers for stabilizing aqueous suspensions or dispersions of minerals and/or fillers and/or pigments (slurries) with regard to infestation or deterioration by microorganisms. | 04-02-2009 |